STOCK TITAN

Encompass Health Corp (EHC) SEC Filings, May 11, 2026

EHC NYSE

Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.

Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.

Rhea-AI Summary

Encompass Health Corporation reported the results of its Annual Meeting held on May 7, 2026. Stockholders voted on electing ten directors, ratifying PricewaterhouseCoopers LLP as independent auditor, and approving the compensation of named executive officers.

There were 99,565,304 common shares outstanding as of the record date, with each share entitled to one vote. Votes representing 92.5% of the combined voting power were present by proxy. All ten director nominees received strong support, with votes for each nominee ranging from about 83.9 million to 85.9 million.

Ratification of PricewaterhouseCoopers LLP passed with 88,444,873 votes for, 3,608,490 against, and 68,452 abstentions. The advisory vote on executive compensation (say-on-pay) passed with 83,410,829 votes for, 3,006,776 against, and 102,636 abstentions, along with 5,601,574 broker non-votes on both the director and compensation proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
current report
-
Rhea-AI Summary

O'Connor Kevin J. reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Kevin J. O'Connor received a grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at no cash cost as part of his annual restricted stock unit grant under the Corporation's 2025 Omnibus Performance Incentive Plan. Following this equity award, O'Connor directly holds 11,563 shares of Encompass Health Common Stock, reflecting a routine compensation-related increase in his ownership stake.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
-
Rhea-AI Summary

Christie Edward M III reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp reported that director Edward M. Christie III received an annual equity award in the form of 1,634 shares of Encompass Health Common Stock on May 7, 2026. The shares were granted at $0.00 per share as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan, meaning they are compensation rather than a market purchase.

After this award, Christie directly owns 9,086 shares of Encompass Health Common Stock. This is a routine director compensation grant, not an open‑market buy or sale, and it does not reflect a discretionary trading decision.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
Rhea-AI Summary

Reidy Christopher R reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Christopher R. Reidy received an equity grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at a price of $0.00 per share as part of his annual grant of restricted stock units under the corporation's 2025 Omnibus Performance Incentive Plan.

Following this grant, Reidy directly holds 17,437 shares of Encompass Health Common Stock. This transaction reflects a compensation-related award rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
-
Rhea-AI Summary

Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Cain A. Hayes reported receiving an annual grant of 1,634 shares of Encompass Health Common Stock, awarded as restricted stock units under the corporation's 2025 Omnibus Performance Incentive Plan. After this compensation-related award, Hayes directly holds 2,092 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
-
Rhea-AI Summary

CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Greg D. Carmichael received an equity award of 1,634 shares of Encompass Health Common Stock. The shares were granted on 2026-05-07 as an annual grant of restricted stock units under the Corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, Carmichael directly holds 20,320 shares of Encompass Health Common Stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
Rhea-AI Summary

Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Terrance Williams received an equity grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at no cash cost as an annual grant of restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan, bringing his direct holdings to 16,830 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
-
Rhea-AI Summary

KATZ LESLYE G reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Leslye G. Katz received an annual grant of 1,634 shares of Encompass Health Common Stock on May 7, 2026. The award was granted at no cash cost as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan.

Following this grant, Katz directly holds 49,558 shares of Encompass Health Common Stock. This is a routine equity compensation award rather than an open-market purchase or sale, so it does not reflect a discretionary trading decision in the company’s stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
-
Rhea-AI Summary

HERMAN JOAN E reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Joan E. Herman received a grant of 1,634 Encompass Health common shares as a compensation award. The shares were granted at no cash cost to Herman as part of an annual restricted stock unit award under the corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, Herman directly holds 49,558 shares of Encompass Health common stock. This is a routine equity compensation grant rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider
Rhea-AI Summary

SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.

Encompass Health Corp director Nancy M. Schlichting received an annual grant of 1,634 restricted stock units of Encompass Health Common Stock at no cost under the corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, she directly holds 22,932 shares of Encompass Health Common Stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
insider

FAQ

How many Encompass Health (EHC) SEC filings are available on StockTitan?

StockTitan tracks 128 SEC filings for Encompass Health (EHC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Encompass Health (EHC)?

The most recent SEC filing for Encompass Health (EHC) was filed on May 11, 2026.